Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 10/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3028483 | 1.00 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL14311499 | 1.00 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL14287268 | 0.92 | DRD2 (0.36) | CHRM3CARM1 | |
| SCHEMBL4371300 | 0.91 | ADORA2A (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL8102952 | 0.90 | ADORA2A (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL14287279 | 0.90 | HTR6 (0.37) | HTR6CARM1 | |
| SCHEMBL3841662 | 0.89 | SLC6A5 (0.42) | — | |
| SCHEMBL3838812 | 0.89 | SLC6A5 (0.42) | — | |
| SCHEMBL3025356 | 0.88 | F12 (0.33) | — | |
| SCHEMBL3025360 | 0.88 | F12 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | claimed |
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | AROS PHARMA APS (DK) | 2007-08-16 | — | — | US | claimed |
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | AROS PHARMA APS (DK) | 2010-08-05 | — | — | US | disclosed |
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | AROS PHARMA APS (DK) | 2010-08-05 | — | — | US | disclosed |
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | AROS PHARMA APS (DK) | 2010-08-05 | — | — | US | disclosed |
| US-7718641-B2 | Pyrrolo [3,4-H] isoquinoline compounds and methods for modulating gated ion channels | AROS PHARMA APS (DE) | 2010-05-18 | — | — | US | disclosed |
| US-7718641-B2 | Pyrrolo [3,4-H] isoquinoline compounds and methods for modulating gated ion channels | AROS PHARMA APS (DE) | 2010-05-18 | — | — | US | disclosed |
| US-7718641-B2 | Pyrrolo [3,4-H] isoquinoline compounds and methods for modulating gated ion channels | AROS PHARMA APS (DE) | 2010-05-18 | — | — | US | disclosed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| WO-2008144931-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-04 | — | — | WO | disclosed |
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | AROS PHARMA APS (DK) | 2007-08-16 | — | — | US | disclosed |
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | AROS PHARMA APS (DK) | 2007-08-16 | — | — | US | disclosed |
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | AROS PHARMA APS (DK) | 2007-08-16 | — | — | US | disclosed |
| WO-2007059608-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | CHRM2 472/4885CHRM4 255/4885CHRM5 263/4885 |
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | CHRM2 472/4885CHRM4 255/4885CHRM5 263/4885 |
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | KCNQ1, KCNQ2, KCNH3 | CHRM2 1113/4885CHRM4 349/4885CHRM5 611/4885 |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | ASIC1, ASIC3, TRPV1 | CHRM2 1030/4885CHRM4 688/4885CHRM5 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.